Skip to main content
TipRanks
Go Ultimate75% OFF

MindMaze Therapeutics Holding SA (MMTX) AI Stock Analysis

4 Followers
CH:MMTX

MindMaze Therapeutics Holding SA

(Six Swiss:MMTX)

Select Model
Rating:41Neutral
Price Target:CHF 1.00â–²(629.93% Upside)
Action:reiterated
Date:01/24/26

The score is primarily held back by weak financial fundamentals (continued losses and negative free cash flow) and bearish technicals (below major moving averages with negative MACD). Valuation does not provide support because the company is unprofitable and no dividend yield is available.

Positive Factors
High gross marginA gross margin of ~69% provides a durable structural cushion versus peers, implying product or cost advantages on core offerings. Sustained high gross margins give management flexibility to invest in R&D and commercialization while dampening the revenue growth needed to approach operating profitability over time.
Negative Factors
Persistent negative profitabilityOngoing net losses and negative operating margins indicate the core business is not yet self-sustaining. Over the medium term the company must either achieve sustained positive operating leverage or secure repeated external funding, otherwise cash burn will constrain R&D and commercialization plans.

MindMaze Therapeutics Holding SA (MMTX) vs. iShares MSCI Switzerland ETF (EWL)

-100%-75%-50%-25%0%25%CH:MMTX-94.65%EWL+16.90%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CHF 24.80M
Dividend Yield
―
Average Volume (3M)
1.05M
Price to Earnings (P/E)
-2.1
Beta (1Y)
0.16
Revenue Growth
―
EPS Growth
―
Country
Switzerland
Employees
10
Sector
General
Sector Strength
55
Industry
Biotechnology

MindMaze Therapeutics Holding SA Business Overview & Revenue Model

Company Description

MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neur...

How the Company Makes Money

RELIEF THERAPEUTICS generates revenue through multiple channels, including the development and licensing of its drug candidates to pharmaceutical companies, which may involve milestone payments and royalties on sales. The company may also engage in s...

MindMaze Therapeutics Holding SA Financial Statement Overview

Summary

Revenue growth and improved gross margin are positives, and leverage is low with a strong equity ratio. However, ongoing net losses, negative EBIT/EBITDA margins, and negative free cash flow keep overall financial strength weak.

Income Statement

35Negative

Balance Sheet

45Neutral

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.05M8.42M6.03M6.08M3.32M0
Gross Profit-1.18M5.84M4.11M4.83M-8.59M0
EBITDA-18.22M-16.73M-108.04M-50.26M-32.69M-6.09M
Net Income-17.04M-17.12M-98.18M-50.79M-34.70M-7.83M
Balance Sheet
Total Assets47.99M53.22M76.39M188.80M251.62M78.05M
Cash, Cash Equivalents and Short-Term Investments12.50M15.08M14.56M19.24M44.76M43.15M
Total Debt1.90M2.14M2.96M4.34M4.26M891.00K
Total Liabilities15.35M16.56M24.16M43.38M70.09M11.00M
Stockholders Equity32.63M36.66M52.23M145.42M181.53M67.04M
Cash Flow
Free Cash Flow-3.43M-3.09M-18.06M-24.63M-49.42M-18.23M
Operating Cash Flow-3.40M-2.92M-17.61M-24.11M-35.71M-18.23M
Investing Cash Flow5.59M4.40M8.70M-8.02M-30.27M3.00M
Financing Cash Flow-303.00K-862.00K4.05M6.42M67.69M58.18M

MindMaze Therapeutics Holding SA Technical Analysis

Technical Analysis SentimentNegative
Last Price0.14

Price Trends

50DMA0.15Negative
100DMA0.17Negative
200DMA0.32Negative

Market Momentum

MACD-0.00Positive
RSI43.70Neutral
STOCH28.57Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MMTX, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.15, and below the 200-day MA of 0.32, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 43.70 is Neutral, neither overbought nor oversold. The STOCH value of 28.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MMTX.

MindMaze Therapeutics Holding SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

CH:MMTX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CH:BSLNCH:BSLN80OutperformCHF 885.12M16.88――4.74%-28.96%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
CH:SANNCH:SANN52NeutralCHF 217.91M-6.24354.99%―107.08%55.54%
CH:NWRNCH:NWRN45NeutralCHF 183.50M-6.40258.11%―-82.88%-212.48%
CH:IDIACH:IDIA41NeutralCHF 1.07B-3.58――-5.32%-95.96%
CH:MMTXCH:MMTX41NeutralCHF 24.80M-2.13-49.18%―――
CH:MOLNCH:MOLN38UnderperformCHF 94.88M-1.74-79.25%――16.86%

* General Sector Average

Performance Comparison

-50%0%50%100%CH:MMTXCH:MOLNCH:BSLNCH:IDIACH:NWRNCH:SANNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:MMTX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CH:MMTXMindMaze Therapeutics Holding SA0.14-2.43-94.66%
CH:MOLNMolecular Partners2.35-0.88-27.13%
CH:BSLNBasilea Pharmaceutica71.9024.1550.58%
CH:IDIAIdorsia Ltd3.970.7322.34%
CH:NWRNNewron Pharmaceuticals SpA8.64-7.28-45.73%
CH:SANNSanthera Pharmaceuticals Holding Ag14.221.9215.61%

MindMaze Therapeutics Holding SA Corporate Events

MindMaze Sets Global Reimbursement Framework to Scale AI-Powered Neurorehabilitation

Dec 23, 2025

MindMaze Therapeutics has detailed a coordinated global reimbursement strategy designed to scale access to its next-generation digital neurorehabilitation therapies and underpin long-term commercial growth. Central to the plan is a U.S. CMS Category...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jan 23, 2026